Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $23,816.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $59.54, for a total value of $23,816.00. Following the transaction, the vice president now owns 83,478 shares in the company, valued at $4,970,280.12. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $53.92, for a total value of $21,568.00.

ANI Pharmaceuticals Trading Down 0.4 %

Shares of NASDAQ ANIP opened at $59.73 on Friday. The firm’s 50 day moving average price is $57.05 and its 200-day moving average price is $58.24. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market cap of $1.26 billion, a PE ratio of -108.60 and a beta of 0.74.

Analyst Upgrades and Downgrades

ANIP has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $77.71.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV boosted its position in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in ANI Pharmaceuticals in the 4th quarter worth about $166,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after buying an additional 579 shares during the last quarter. Finally, Rafferty Asset Management LLC bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $200,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.